Takeda Pharma (TKPYY) 25.3700 $TKPYY
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 198.37 (+3.87), VRTX: 127.31 (+1.10), OVAS: 30.01 (+0.84), MYL: 71.38 (+0.71), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), ALR: 50.79 (+0.04), ONTY: 2.59 (+0.16), CELG: 116.37 (+0.84), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), OREX: 4.98 (-0.03), FCSC: 3.92 (-0.10), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), GWPH: 112.93 (+0.68), CTSO: 6.24 (+0.31), ACHN: 11.03 (+1.46), RMD: 56.81 (+0.61), SNY: 50.40 (-0.12), PBYI: 181.30 (+4.29)
Orexigen Therapeutics: Problems Associated With Early Data Release
Alexander Maxwell - at Seeking Alpha - Fri May 15, 9:48AM CDT
OREX: 4.98 (-0.03)
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 6.42 (+0.21), BAX: 68.25 (-1.11), ACH: 15.85 (-0.48)
Cognitive Impairment - Pipeline Review, H1 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z64d6n/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Dart NeuroScience LLC - Eisai Co., Ltd. - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Iproteos S.L. - Merck & Co., Inc. - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - Neuralstem, Inc. - Novartis AG - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - Sanofi - Shire Plc - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Upsher-Smith Laboratories, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/z64d6n/cognitive
PFE: 33.98 (-0.01), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), AZN: 68.74 (-0.55), MRK: 60.01 (-0.22), SHPG: 254.71 (+0.26), TEVA: 60.19 (-0.04), ABBV: 65.61 (-0.38), CUR: 1.71 (+0.01), NVS: 104.06 (+0.31)
Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 12:10PM CDT
Orexigen (OREX) and partner Takeda (TKPYY) have decided to terminate the Light study on their obesity drug, Contrave.
OREX: 4.98 (-0.03), GILD: 111.00 (+1.70), ATHX: 1.33 (+0.06)
How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 4.98 (-0.03)
Why Shares of Orexigen Therapeutics, Inc. Cratered Today
George Budwell, The Motley Fool - Motley Fool - Wed May 13, 10:48AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Orexigen Therapeutics continued their...
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT
OREX: 4.98 (-0.03)
Why It's Lights Out for Orexigen Therapeutics, Inc.
Sean Williams, The Motley Fool - Motley Fool - Tue May 12, 2:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
5 Largest Markets for Pharmaceuticals
Cheryl Swanson, The Motley Fool - Motley Fool - Tue May 12, 9:26AM CDT
Source: Flickr, Creative Commons. If you're a biotech or Big Pharma company, your world is not only growing, it's standing on its head. According to the Institute for Healthcare Informatics, worldwide spending for prescription branded drugs and...
ABT: 48.84 (+0.13), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31)
Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl)
PR Newswire - Tue May 12, 7:30AM CDT
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors. The Light Study is not being terminated due to a finding of superiority or harm. The ESC, Takeda and Orexigen expect to report the final Light Study data in a scientific forum after all of the CV events in the Light Study have been collected and properly adjudicated.
OREX: 4.98 (-0.03)
First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT
Actos Lawsuit Settlement News: Takeda Agrees to Pay $2.3 Billion Settlement, Says Lawsuitsettlementnews.com
PR Newswire - Tue May 12, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co. has agreed to pay $2.37 billion to settle approximately 8,000 federal and state lawsuits over its drug Actos. The 8K cases include 3,500 lawsuits in Lafayette, Louisiana before U.S. District Judge Rebecca Doherty (In Re: Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana), and about 4,500 suits in California, Pennsylvania, Illinois, and West Virginia, according to Bloomberg News. The claimants alleged that Takeda hid the bladder cancer risks of the diabetes drug, however, according to Drug Watch, Takeda insists that the benefits of Actos far outweigh the side effects.
Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as Maintenance Therapy for Newly Diagnosed Multiple Myeloma
Business Wire - Tue May 12, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib. This is a superiority study designed to demonstrate whether sustained proteasome inhibition, delivered orally, improves the long term clinical outcomes of people living with multiple myeloma.
Orexigen's Q1 Loss Narrower than Expected, Contrave Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:55PM CDT
Orexigen Therapeutics (OREX) reported a first-quarter 2015 loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 23 cents.
OREX: 4.98 (-0.03), ACT: 295.76 (-0.84)
Idiopathic (Essential) Hypertension Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ftwwp9/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - Jiangsu Hengrui Medicine Co., Ltd. - Lee's Pharmaceutical Holdings Limited - PhaseBio Pharmaceuticals, Inc. - Quantum Genomics SA - Takeda Pharmaceutical Company Limited Drug Profiles - (amlodipine besylate azilsartan medoxomil hydrochlorothiazide) - (amlodipine besylate candesartan) - (nifedipine candesartan cilexetil) - azilsartan medoxomil - carvedilol phosphate ER - - carvedilol SR - CS-3150 - LY-2623091 - PB-1120 - QGC-001 - rostafuroxin For more information visit http://www.researchandmarkets.com/research/ftwwp9/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 72.94 (+0.04)
Seattle Genetics Posts Narrower-than-Expected Loss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 04, 11:50AM CDT
Seattle Genetics, Inc. (SGEN) reported a loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
SGEN: 40.50 (+0.56), HZNP: 29.20 (+0.17)
Actos Settlement Reached: Takeda Agrees to Pay $2.3 Billion to Settle Approximately 8K Cases, Says Legal-Bay
PR Newswire - Mon May 04, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Takeda Pharmaceutical Co. has agreed to pay approximately $2.37 billion to settle approximately 8K cases in which claimants accused the company of hiding cancer risks associated with diabetes drug, Actos. According to Bloomberg News, Takeda officials stated that if 95% of plaintiffs agree to participate in the settlement, the drug maker will put the money into a settlement fund. The settlement values would be more than $296,000 per case for plaintiffs who participate in the settlement; however, the payment may be reduced depending on age, smoking history, and toxin exposure. Also according to Bloomberg, if 97% of plaintiffs sign up, Takeda would add $300 million, raising the settlement to $2.4 billion.
Actos Litigation News: Cut-Off for Inclusion in $2.4 Billion Actos Settlement Is Noon Friday, May 1, 2015, Parker Waichman LLP Comments
PRWeb - Thu Apr 30, 12:41PM CDT
Parker Waichman LLP, a national law firm that is actively involved in Actos (pioglitazone) litigation and which has long been dedicated to the protecting the rights of victims who have been injured by drugs and medical devices, is commenting on developments in the ongoing Actos litigation. Takeda Pharmaceutical Company, the maker of the diabetes medication, Actos, has agreed to a $2.4 billion settlement to resolve lawsuits in the United States brought over allegations that Takeda hid cancer risks associated with Actos, according to a Bloomberg Business News report dated April 28, 2015. The consolidated Actos cases in Louisiana are In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette).
$2.4 Billion Settlement Reached in Actos Bladder Cancer Products Liability Litigation
PR Newswire - Tue Apr 28, 8:35PM CDT
The court-appointed Plaintiffs' Steering Committee ("PSC"
of the national litigation involving the diabetes drug, Actos, is pleased to announce the resolution of what is expected to be 9,000 claims of individuals who were diagnosed with bladder cancer after taking Actos through a global settlement program.
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 198.37 (+3.87), VRTX: 127.31 (+1.10), OVAS: 30.01 (+0.84), MYL: 71.38 (+0.71), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), ALR: 50.79 (+0.04), ONTY: 2.59 (+0.16), CELG: 116.37 (+0.84), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), OREX: 4.98 (-0.03), FCSC: 3.92 (-0.10), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), GWPH: 112.93 (+0.68), CTSO: 6.24 (+0.31), ACHN: 11.03 (+1.46), RMD: 56.81 (+0.61), SNY: 50.40 (-0.12), PBYI: 181.30 (+4.29)
Orexigen Therapeutics: Problems Associated With Early Data Release
Alexander Maxwell - at Seeking Alpha - Fri May 15, 9:48AM CDT
OREX: 4.98 (-0.03)
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 6.42 (+0.21), BAX: 68.25 (-1.11), ACH: 15.85 (-0.48)
Cognitive Impairment - Pipeline Review, H1 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z64d6n/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Dart NeuroScience LLC - Eisai Co., Ltd. - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Iproteos S.L. - Merck & Co., Inc. - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - Neuralstem, Inc. - Novartis AG - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - Sanofi - Shire Plc - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Upsher-Smith Laboratories, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/z64d6n/cognitive
PFE: 33.98 (-0.01), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), AZN: 68.74 (-0.55), MRK: 60.01 (-0.22), SHPG: 254.71 (+0.26), TEVA: 60.19 (-0.04), ABBV: 65.61 (-0.38), CUR: 1.71 (+0.01), NVS: 104.06 (+0.31)
Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 12:10PM CDT
Orexigen (OREX) and partner Takeda (TKPYY) have decided to terminate the Light study on their obesity drug, Contrave.
OREX: 4.98 (-0.03), GILD: 111.00 (+1.70), ATHX: 1.33 (+0.06)
How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 4.98 (-0.03)
Why Shares of Orexigen Therapeutics, Inc. Cratered Today
George Budwell, The Motley Fool - Motley Fool - Wed May 13, 10:48AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Orexigen Therapeutics continued their...
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT
OREX: 4.98 (-0.03)
Why It's Lights Out for Orexigen Therapeutics, Inc.
Sean Williams, The Motley Fool - Motley Fool - Tue May 12, 2:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 4.98 (-0.03), VVUS: 2.56 (+0.05), ARNA: 4.39 (+0.14)
5 Largest Markets for Pharmaceuticals
Cheryl Swanson, The Motley Fool - Motley Fool - Tue May 12, 9:26AM CDT
Source: Flickr, Creative Commons. If you're a biotech or Big Pharma company, your world is not only growing, it's standing on its head. According to the Institute for Healthcare Informatics, worldwide spending for prescription branded drugs and...
ABT: 48.84 (+0.13), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31)
Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl)
PR Newswire - Tue May 12, 7:30AM CDT
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors. The Light Study is not being terminated due to a finding of superiority or harm. The ESC, Takeda and Orexigen expect to report the final Light Study data in a scientific forum after all of the CV events in the Light Study have been collected and properly adjudicated.
OREX: 4.98 (-0.03)
First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT
Actos Lawsuit Settlement News: Takeda Agrees to Pay $2.3 Billion Settlement, Says Lawsuitsettlementnews.com
PR Newswire - Tue May 12, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co. has agreed to pay $2.37 billion to settle approximately 8,000 federal and state lawsuits over its drug Actos. The 8K cases include 3,500 lawsuits in Lafayette, Louisiana before U.S. District Judge Rebecca Doherty (In Re: Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana), and about 4,500 suits in California, Pennsylvania, Illinois, and West Virginia, according to Bloomberg News. The claimants alleged that Takeda hid the bladder cancer risks of the diabetes drug, however, according to Drug Watch, Takeda insists that the benefits of Actos far outweigh the side effects.
Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as Maintenance Therapy for Newly Diagnosed Multiple Myeloma
Business Wire - Tue May 12, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib. This is a superiority study designed to demonstrate whether sustained proteasome inhibition, delivered orally, improves the long term clinical outcomes of people living with multiple myeloma.
Orexigen's Q1 Loss Narrower than Expected, Contrave Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:55PM CDT
Orexigen Therapeutics (OREX) reported a first-quarter 2015 loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 23 cents.
OREX: 4.98 (-0.03), ACT: 295.76 (-0.84)
Idiopathic (Essential) Hypertension Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ftwwp9/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - Jiangsu Hengrui Medicine Co., Ltd. - Lee's Pharmaceutical Holdings Limited - PhaseBio Pharmaceuticals, Inc. - Quantum Genomics SA - Takeda Pharmaceutical Company Limited Drug Profiles - (amlodipine besylate azilsartan medoxomil hydrochlorothiazide) - (amlodipine besylate candesartan) - (nifedipine candesartan cilexetil) - azilsartan medoxomil - carvedilol phosphate ER - - carvedilol SR - CS-3150 - LY-2623091 - PB-1120 - QGC-001 - rostafuroxin For more information visit http://www.researchandmarkets.com/research/ftwwp9/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 72.94 (+0.04)
Seattle Genetics Posts Narrower-than-Expected Loss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 04, 11:50AM CDT
Seattle Genetics, Inc. (SGEN) reported a loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
SGEN: 40.50 (+0.56), HZNP: 29.20 (+0.17)
Actos Settlement Reached: Takeda Agrees to Pay $2.3 Billion to Settle Approximately 8K Cases, Says Legal-Bay
PR Newswire - Mon May 04, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Takeda Pharmaceutical Co. has agreed to pay approximately $2.37 billion to settle approximately 8K cases in which claimants accused the company of hiding cancer risks associated with diabetes drug, Actos. According to Bloomberg News, Takeda officials stated that if 95% of plaintiffs agree to participate in the settlement, the drug maker will put the money into a settlement fund. The settlement values would be more than $296,000 per case for plaintiffs who participate in the settlement; however, the payment may be reduced depending on age, smoking history, and toxin exposure. Also according to Bloomberg, if 97% of plaintiffs sign up, Takeda would add $300 million, raising the settlement to $2.4 billion.
Actos Litigation News: Cut-Off for Inclusion in $2.4 Billion Actos Settlement Is Noon Friday, May 1, 2015, Parker Waichman LLP Comments
PRWeb - Thu Apr 30, 12:41PM CDT
Parker Waichman LLP, a national law firm that is actively involved in Actos (pioglitazone) litigation and which has long been dedicated to the protecting the rights of victims who have been injured by drugs and medical devices, is commenting on developments in the ongoing Actos litigation. Takeda Pharmaceutical Company, the maker of the diabetes medication, Actos, has agreed to a $2.4 billion settlement to resolve lawsuits in the United States brought over allegations that Takeda hid cancer risks associated with Actos, according to a Bloomberg Business News report dated April 28, 2015. The consolidated Actos cases in Louisiana are In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette).
$2.4 Billion Settlement Reached in Actos Bladder Cancer Products Liability Litigation
PR Newswire - Tue Apr 28, 8:35PM CDT
The court-appointed Plaintiffs' Steering Committee ("PSC"
of the national litigation involving the diabetes drug, Actos, is pleased to announce the resolution of what is expected to be 9,000 claims of individuals who were diagnosed with bladder cancer after taking Actos through a global settlement program. 
